Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir

Jung Hyun Lim, MD\textsuperscript{a}, Jung Hwan Yu, MD, PhD\textsuperscript{a,*}, Young Ju Suh, PhD\textsuperscript{b}, Jin-Woo Lee, MD, PhD\textsuperscript{a}, Young-Joo Jin, MD, PhD\textsuperscript{a,\textcopyright}

Abstract
This study evaluated the clinical implications of hepatitis B surface antigen quantification (qHBs Ag) in chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) and identified the association between qHBs Ag and the risk of hepatocellular carcinoma (HCC) in these patients. Between January 2007 and December 2018, the qHBs Ag and clinical data of 183 CHB patients who initially received ETV (n = 45, 24.6%) or TDF (n = 138, 75.4%) were analyzed. The mean follow-up period of the 183 CHB patients was 45.3 months, of which 59 (32.2%) patients showed a reduction in qHBs Ag by >50% after 1 year of antiviral treatment (ETV or TDF). The HCC development (P = .179) or qHBs Ag reduction (P = .524) were similar in the ETV and TDF groups. Patients with a >50% decrease in qHBs Ag had a significantly lower incidence of HCC or decompensated cirrhosis complications (P = .005). Multivariate analysis showed that a >50% reduction of qHBs Ag (hazard ratio 0.085, P = .018) and the presence of cirrhosis (hazard ratio 3.32, P = .016) were independent factors predicting the development of HCC.

Patients whose qHBs Ag value decreased >50% at 1 year after antiviral treatment for CHB showed a significant decrease in HCC or decompensated cirrhosis events. A reduction in qHBs Ag could be used as a predictive factor of HCC development or critical complications in CHB patients treated with TDF or ETV.

Abbreviations: AFP = alpha-fetoprotein, ALT = alanine aminotransferase, cccDNA = closed circular DNA, CHB = chronic hepatitis B, CI = confidence intervals, CT = computed tomography (CT), CTP = Child-Turcotte-Pugh classification, dsDNA = a double stranded linear DNA, ETV = entecavir, HBs Ag = hepatitis B envelope antigen, HCC = hepatocellular carcinoma, OR = odds ratios, Peg-IFN-\(\alpha\) = pegylated interferon-alpha, qHBs = Ag, hepatitis B surface antigen quantification, rcDNA = a relaxed circular DNA, TDF = tenofovir disoproxil fumarate.

Keywords: chronic hepatitis B, entecavir, HBs Ag quantification, hepatocellular carcinoma, tenofovir disoproxil fumarate

1. Introduction
Hepatitis B virus (HBV) is a leading cause of cirrhosis and hepatocellular carcinoma (HCC) and is known to affect more than 2.5 million people worldwide.\textsuperscript{[1]} Since HCC is closely associated with chronic hepatitis B (CHB) infection,\textsuperscript{[2,3]} oral antiviral therapy for HBV can improve the prognoses of CHB patients by preventing the development of HCC and decompensated complications of cirrhosis.\textsuperscript{[4]} In particular, drugs with a high barrier to resistance, such as entecavir (ETV) or tenofovir (TDF),\textsuperscript{[5,6]} which are recommended as a first treatment drugs for CHB,\textsuperscript{[7–10]} have a long-term antiviral effects in more than 95% of CHB patients, and have the effect of restoring liver function.\textsuperscript{[11–13]} On the other hand, despite the use of highly potent antiviral drugs, the risk of HCC remain in patients with CHB.\textsuperscript{[14–16]} Therefore, assessing the risk of HCC in these patients and finding the factors associated with HCC is an important issue.

HBs Ag quantification (qHBs Ag) has been studied to date primarily as a predictor of HBs Ag seroconversion or HBs Ag clearance after pegylated interferon-\(\alpha\) (Peg-IFN-\(\alpha\)) or nucleos (\(\prime\))ides analogue therapy.\textsuperscript{[17–19]} Recently, however, qHBs Ag has become increasingly recognized as a marker for predicting HCC and the development of cirrhosis in CHB patients.\textsuperscript{[20,21]} A recent
meta-analysis involving 6028 patients with CHB reported a greater risk of HCC in patients with high serum HBsAg levels (≥1000 IU/mL) than that among patients with low HBsAg levels.[22] Similarly, a systemic review showed that the cumulative incidence of HCC over a 14-year follow-up increased when HBsAg was higher in a dose-response manner.[20] However, studies on the risk of qHBsAg and HCC in CHB patients treated with highly potent antiviral drugs, such as ETV and TDF, which are used widely, are still lacking. Moreover, little is known regarding the differences between these 2 antiviral agents in qHBsAg reduction.

Therefore, in this study, we intended to assess the predictive power of qHBsAg for HCC development and critical event risk in CHB patients initially treated with ETV or TDF, and to identify the clinical implication of HBsAg in these patients. In addition, we tried to find out the difference in the reduction of HBsAg between the 2 drugs, ETV and TDF.

2. Patients and methods

2.1. Study subjects

A study population of 899 CHB patients registered between January 2007 and December 2018 received ETV or TDF as an initial treatment for CHB infection. All of them had been HBsAg-positive for longer than six months and had undergone antiviral therapy for a CHB infection according to the guidelines published by the American Association for the Study of Liver Diseases (AASLD).[7] The HBsAg quantitative values of all enrolled patients were measured immediately before ETV or TDF administration, and then every 6 months at a regular follow-up for >5 years at Inha University Hospital. The method of measuring the HBsAg quantitative value in all patients was the Architect HBsAg QT (Abbott Diagnostics, Wiesbaden, Germany). ETV and TDF have been available at the authors’ hospital since 2007 and 2012, respectively.

Patients with another chronic liver disease, such as hepatitis C virus infection, alcoholic liver disease, primary biliary cirrhosis, Wilson disease, autoimmune hepatitis, or those aged ≤18 years were excluded. In addition, patients with a current HCC or another malignancy at the start of antiviral therapy (n = 61) or with a follow-up duration <6 months after antiviral therapy (n = 28) were excluded. All patients whose HBsAg quantitative values were missing from the beginning (n = 627) were also excluded (Fig. 1). Accordingly, 183 CHB patients treated with ETV (n = 45, 24.6%) or TDF (n = 138, 75.4%) were enrolled in this study, and their electronic medical records were analyzed retrospectively. The study was approved by the Institutional Review Board of Inha University Hospital, Incheon, South Korea (Approval number: INHAUH 2020-11-014).

2.2. Recruitment of clinical data

The demographic data of the patients, liver function tests, and presence of liver cirrhosis, serum alpha-fetoprotein (AFP) level, Child-Turcotte-Pugh classification, hepatitis B envelope antigen (HBsAg) and its seroconversion, and HBV DNA (Copies/mL) levels were collected from the electronic medical records and clinical history. The quantitative value of HBsAg (IU/mL) was measured using Abbott quantification device at Inha University Hospital. The HBV DNA quantitative level was measured using a hybridization assay (a detection limit of 2000 copies/mL) at the start of antiviral therapy. Liver cirrhosis was diagnosed from the clinical evidence of portal hypertension (esophageal varices, ascites, encephalopathy, splenomegaly, or low platelet count) or by liver ultrasonography.[23,24]

2.3. Surveillance of HCC

To assess HCC development, the patients were routinely tested for the serum AFP and liver US or liver computed tomography
The baseline clinical characteristics of the 183 patients. The median patient age was 49.4 years (range, 18–79 years), and 97 (53%) were male. LC was present in 79 (43.2%) patients, and most (97.4%) of these patients were in a compensated state with Child-Turcotte-Pugh class A or B. HBeAg was positive in 95 (51.9%) patients. The median follow-up duration was 45.4 months (range, 3.1–96.6 months). The study subjects were divided into 2 groups: one showed a >50% reduction in quantitative HBs Ag (qHBs Ag) levels after 1 year of antiviral treatment (reduction group), and the other group showing a reduction of less than 50% or an increase (nonreduction group). Of the 183 patients, 124 (67.8%) patients were in the nonreduction group, and 59 (32.2%) patients were in the reduction group. At the start time of antiviral therapy, there were no significant differences in both groups. Only the average follow-up duration was 6 months longer in the reduction group (49.7 months) than the nonreduction group (43.4 months) ($P = .046$).

### 3. Results

#### 3.1. Baseline characteristics

Table 1 lists the baseline characteristics of the 183 patients. The median patient age was 49.4 years (range, 18–79 years), and 97 (53%) were male. LC was present in 79 (43.2%) patients, and most (97.4%) of these patients were in a compensated state with Child-Turcotte-Pugh class A or B. HBeAg was positive in 95 (51.9%) patients. The median follow-up duration was 45.4 months (range, 3.1–96.6 months). The study subjects were divided into 2 groups: one showed a >50% reduction in quantitative HBs Ag (qHBs Ag) levels after 1 year of antiviral treatment (reduction group), and the other group showing a reduction of less than 50% or an increase (nonreduction group). Of the 183 patients, 124 (67.8%) patients were in the nonreduction group, and 59 (32.2%) patients were in the reduction group. At the start time of antiviral therapy, there were no significant differences in both groups. Only the average follow-up duration was 6 months longer in the reduction group (49.7 months) than the nonreduction group (43.4 months) ($P = .046$).

#### 3.2. Cumulative critical event development in CHB patients treated with ETV or TDF

A critical event that can occur due to a CHB infection was defined in the present study as the development of decompensation (ascites, variceal bleeding, jaundice, spontaneous bacterial peritonitis, and hepatic encephalopathy), the occurrence of HCC, and death. Over the median follow-up period of 45.4 months, critical events developed in 22 (12.0%) of the 183 study subjects, regardless of antiviral agents used (Table 2). Of them, 15 patients (68%) had cirrhosis at a relatively larger rate than the no critical event group ($P = .020$), as expected. Among the hematological tests, albumin, the total bilirubin, PT, and AFP did not significantly differ between the 2 groups. Only ALT showed higher patterns in the noncritical event group ($P = .019$).

Graphing the difference in the qHBs Ag log values for all patients over 5 years confirmed an overall decrease. Figure 2A shows the mean qHBs Ag decline from baseline for all patients and Figure 2B shows the mean decline divided between ETV-treated patients and TDF-treated patients (Fig. 2). The data in Figure 2 panel B seems to show a more consistent decrease over time in the group of patients taking TDF. However, the number of patients who decreased by <50% or increased in the ETV group was not significantly greater than that of the TDF group ($P = .205$). There was no statistically significant difference, but the number of initial HBe Ag-positive patients in the ETV group relatively small compared to the TDF group ($P = .086$). So, the
The reduction rate of qHBs Ag in the ETV group was smaller than that in the TDF group, which may have been shown in the graph.

Among the 22 patients with critical events, only 1 patient (4.5%) whose qHBs Ag level decreased by $\geq 50\%$ after 1 year of antiviral therapy was included. Other patients with qHBs Ag $\geq 50\%$ reduction, after 1 year of antiviral therapy had a rarer occurrence of critical events during the follow-up period compared to the group with a decrease of $< 50\%$ or an increase ($P = .003$). Figure 3 presents the 5-year cumulative critical event development rate. The cumulative critical event development rate was significantly higher in the nonreduction group than in the reduction group (Fig. 3A). Alternatively, an analysis of the qHBs Ag levels divided by a $\geq 50\%$ decrease (group A), 0 to 50% decrease (group B), and increased group (group C) revealed significant differences in the cumulative critical event development rate (Fig. 3B). The incidence of critical events for group A was significantly lower than that of groups B ($P = .019$) and C ($P = .005$). No significant difference was observed between groups B and C ($P = .623$).

### 3.3. Clinical characteristics of HCCs that developed during ETV or TDF therapy

In the 13 HCC patients, the median tumor size was 2.269 cm (range, 1.0–4.3 cm), and the number of tumors was one (100.0%) in HCC patients. All HCCs (100%) were of the nodular type, and the median AFP level at HCC diagnosis was 79.938 ng/mL. PVT was absent in all patients, and the BCLC stages were zero in 7 (53.8%), A in 5 (38.5%), and C in 1 (7.7%). Most (92.3%) were within the Milan criteria. Beyond the Milan criteria, HCC was observed in 1 patient. The patient was a 56-year-old man who had obstructive jaundice. The HCC was solitary, and the size was approximately 3.2 cm, but the tumor of this patient was an intrahepatic bile duct HCC (icteric-type HCC) containing confluen and right and left hepatic ducts.

---

**Table 2**

| Variables                          | Total (n = 183) | Event group (n = 22, 12.0%) | No event group (n = 161, 88.0%) | $P$  |
|-----------------------------------|----------------|-----------------------------|----------------------------------|-----|
| Age, years $^+$                    | 49.4 (15–79)   | 47.7 (24–70)                | 49.7 (15–79)                     | .486|
| Sex (male), n (%)                  | 97 (53.0)      | 15 (68.2)                   | 82 (50.9)                        | .007|
| ALT, IU/L $^+$                     | 162.0 (13–1871)| 50.8 (13–206)               | 177.2 (14–1871)                  | .019|
| Albumin, mg/dL $^+$               | 4.0 (1.9–5.2)  | 3.9 (2.3–4.6)               | 4.0 (1.9–5.2)                    | .178|
| T-bil, mg/dL $^+$                 | 1.5 (0.1–38.2) | 1.1 (0.3–2.9)               | 1.5 (0.1–38.2)                   | .552|
| PT, INR $^+$                       | 1.12 (0.87–2.07)| 1.17 (0.9–1.65)             | 1.11 (0.87–2.07)                 | .189|
| AFP, ng/mL $^+$                    | 42.9 (0.8–1391)| 16.6 (1.4–202.5)            | 46.5 (0.8–1391)                  | .425|
| LC, present, n (%)                 | 79 (43.2)      | 15 (68.2)                   | 64 (39.8)                        | .020|
| CTP class, A/B/C, n (%)            | 154/27/2 (84.2/14.8/1.1) | 15/70 (82.2/31.8/0)         | 139/20/2 (86.3/12.4/1.2)         | .051|
| HBeAg, positive, n (%)             | 95 (51.9)      | 10 (45.5)                   | 85 (52.8)                        | .650|
| HBeAg loss at 12 mo, yes, n (%)    | 15 (8.2)       | 1 (4.5)                     | 14 (8.7)                         | 1.000|
| HBV-DNA, copies/mL $^+$           | $3.16 \times 10^8$ (57–3.41 $\times 10^8$) | $1.6 \times 10^7$ (57–1.5 $\times 10^8$) | $3.57 \times 10^9$ (88–3.41 $\times 10^9$) | .061|
| HBV-DNA negative at 12 mo, yes, n (%) | 146 (79.8)   | 18 (81.8)                   | 128 (79.5)                       | 1.000|
| $>50\%$ Decreased HBsAg at 12 mo, yes, n (%) | 59 (32.2) | 1 (4.5)                     | 58 (36.0)                        | .003|

$^+$ $P$ values were calculated using the $t$ test or $\chi^2$ test between the event and no event group.  
$^+$ Median (range).
3.4. Clinical characteristics of CHB patients with or without HCC

Supplementary Table 1, http://links.lww.com/MD2/A517 presents the clinical baseline characteristics of the patients with or without HCC. Of the 183 study subjects, HCC developed in 13 patients after the start of antiviral therapy. None of the 13 patients with HCC showed a >50% reduction of qHBs Ag during the follow-up period \( (P = .010) \). Figure 4 shows the cumulative HCC development. The median age was similar (49.3 vs. 49.4). Among the patients with HCC, there were more males (76.9%), but the \( P \) value was not significant \( (P = .088) \). The quantified HBV DNA levels, the presence of HBe Ag, and its seroconversion after 1 year and cirrhosis did not significantly affect the occurrence of HCC \( (P \) values for all >0.05).

3.5. Predictors of HCC and critical event development in CHB patients treated with ETV or TDF

Univariate analysis of all 183 study subjects showed that the presence of LC at a base \( (\text{hazard ratio [HR]} 3.248, P < .015) \) and ≥50% reduction in the qHBs Ag level after 1 year of antiviral therapy \( (\text{HR} 0.085, P < .017) \) were associated with the occurrence of all critical events. Multivariate analysis showed that the presence of LC \( (\text{HR} 3.319, P = .016) \) and ≥50% reduction in the
qHBs Ag level (HR 0.085, P = .018) independently predicted the occurrence of a critical event (Table 3).

A comparison of the cumulative HCC development and critical events between the ETV and TDF group revealed no significant difference (HCC, p = 0.179; critical events, P = .474) (Supplementary Figure 1, http://links.lww.com/MD2/A515). In addition, in the HBe Ag-positive and -negative groups, the qHBs Ag level showed a tendency to decrease less in the HBe Ag-negative group for 3 years, but it still tended to decrease continuously in both groups (Supplementary Figure 2, http://links.lww.com/MD2/A516).

### 4. Discussion

For decades, antiviral drugs with proven therapeutic effects in CHB patients have been developed and used to treat hepatitis B infections. On the other hand, even with treatment, CHB cannot be eradicated completely and the risk of HCC development still remained.\[25\]

Therefore, studies on the serological markers that can be used to monitor continuously the natural history, assess the treatment response, and predict the risk of liver-related complications in CHB patients are conducted alongside treatment. One method, HBsAg quantification, is considered to be strongly related to the total amount of HBV DNA in the body, including HBV DNA in hepatocytes.\[26–29\] In particular, qHBs Ag is known to be a predictor of the antiviral treatment response in patients receiving thePEG-IFN treatment.\[30–32\] Although the qHBs Ag level could not predict the treatment response for patients treated with NAs unlike the PEG-IFN treatment,\[18,19,33,34,35\] the qHBs Ag level is expected to have clinical implications related to the prognosis of CHB patients because it reflects the total amount transcribed from the integrated DNA and ccc DNA.\[36\] When hepatitis B virus infects hepatocytes, it enters in the form of a relaxed circular DNA (rcDNA) genome or a double stranded linear DNA genome. The rcDNA is transformed into closed circular DNA (cccDNA), which serves as a template for replication and is inhibited by ETV or TDF when reverse transcribed in the hepatoplasm. The integrated DNA form is replication-defective, but it can drive carcinogenesis through processes such as genomic truncation and mutation. Viral proteins expressed from integrated HBV genomes have been shown to induce HCC spontaneously or by overexpression, and genomic truncation has shown that the function of HBx proteins is altered to induce carcinogenesis. In the early immune-tolerant phase, the number of infected hepatocytes increases through the replicative pathway using cccDNA. Hepatocytes with integrated DNA are relatively few. However, in the immune clearance phase, hepatocytes with cccDNA are reduced by the host immune system, and hepatocytes with integrated DNA survive and cause chronic infection by clonal expansion and new infection. This mechanism is the proposed process that HBs Ag titer may increase even after ETV or TDF treatment.\[32–34,37–38\]

But, among the present literature, few studies have compared and analyzed the correlation between qHBs Ag and HCC risk after highly potent antiviral drugs, such as ETV or TDF, in treatment-naive CHB patients. In addition, very few studies have individually analyzed HBe-Ag positive and -negative patients. This is notable in that the meaning of qHBs Ag was found to be different between HBe Ag positive and negative patients.\[20,35,39,40\] The present study differs from the previous articles in that the predictive value of qHBs Ag was evaluated by including both HBe Ag-positive and -negative patients using ETV and TDF, which are presently used as primary treatment in the treatment of CHB. Treatment-naive HBe Ag-positive and -negative CHB patients were evaluated retrospectively through the changes in qHBs Ag. Patients showing a ≥50% decrease in the qHBs Ag levels after 1 year were relatively associated with fewer critical events and showed a lower incidence of HCC. Among the 183 study subjects, the qHBs Ag levels of 59 (32.2%) patients decreased by ≥50% after 1 year of antiviral treatment, and only 1 patient (1.7%) had critical events. Notably, patients with no cirrhosis and a rapid decrease in qHBs Ag within 1 year of therapy showed fewer critical events in the present study. In the 50% reduction group, no HCCs occurred during the 5-year follow-up period.

In the present study, the ALT value appeared to be a negative predictive value for the incidence of critical events (P = .019). However, this appears to be due to insurance standards for CHB treatment in Korea.\[119\] As confirmed in the present study, patients with LC have a higher risk of critical events. According to the insurance policy for antiviral therapy initiation criteria in our
country, CHB patients with cirrhosis are authorized to use ETV or TDF regardless of their ALT level. For CHB patients without cirrhosis, however, approval can be obtained only when the ALT level rises above the upper normal limit >2 or 3 times on the premise that there is no other cause for the rise. Therefore, in the present study, patients with CHB but without cirrhosis tended to have higher baseline ALT values before treatment. The follow-up period of patients in the non-50% reduction group was relatively short, presumably due to the higher incidence of HCC development or critical events in patients in this group.

The clinical significance of the qHBs Ag level revealed so far is the diagnosis of HBV infection, the definition of the disease phase, prediction of spontaneous HBs Ag seroconversion, prediction of reactivation in the inactive carrier state, and prediction of virological control after the discontinuation of NA treatment.[43] In a meta-analysis conducted in China with HBe Ag-negative CHB patients treated with NAs, the probability of HBs Ag loss after stopping treatment was higher when the HBs Ag level decreased by ≥1 log IU/mL during 156 weeks of treatment (P < .001).[42] In another systematic review, the virological and clinical relapse rates were estimated to be three times higher when the HBs Ag levels were more than 100 IU/mL at 12 to 24 months after the discontinuation of NA treatment. [43] Despite the many studies on qHBs Ag, few studies have analyzed the risk of cumulative HCC and critical events according to the HBs Ag level after the start of ETV and TDF treatment in treatment-naive CHB patients. Therefore, the cutoff value of the HBs Ag level or clear guidelines for clinical applications has not been established. However, based on the previous studies in which the qHBs Ag level decreased from 0.16 to 0.3 log IU/mL per year during ETV and TDF therapy,[44–47] the cutoff value was set to the value that conferred a 50% reduction after 1 year of treatment. Hence, a significant decrease in qHBs Ag in the first year of ETV and TDF treatment was associated with a low risk of critical events and HCC during the first 5 years of treatment.

The strength of our study is the pioneering analysis of qHBs Ag changes following ETV and TDF treatment in treatment-naive CHB patients, including both HBe Ag-positive and -negative patients. However, we also acknowledge that this study had several limitations. First, it was a single-center study, and the cohort size was relatively small. Although the number of CHB patients (n = 899) initially treated with ETV and TDF in our hospital was not small, the number of patients whose qHBs Ag level were regularly followed up at the initial and 6-months intervals was relatively insufficient. Second, since this study was only for Korean patients with genotype C HBV, there may be limitations in its application to patients with various HBV genotypes in the world. Third, there was a potential selective bias in our retrospective study. Therefore, we believe that a prospective, multinational multicenter study will be needed to support this study in the future.

In conclusion, the HBs Ag level decreased gradually during ETV and TDF therapy in both HBe Ag-positive and -negative CHB patients, and a significant decrease (≥50%) in the HBs Ag level during ETV and TDF treatment may indicate a lower risk of critical events, particularly HCC development. Therefore, monitoring the changes in HBs Ag level during ETV and TDF treatment may provide useful information for predicting the risk of complications in both HBe Ag-positive and -negative treatment-naive CHB patients.

Author contributions
JH Lim, JH Yu, and YJ Jin were responsible for the concept and design of the study, the acquisition, analysis and interpretation of data, and drafting of the manuscript. JW Lee, and YJ Suh helped with data acquisition and interpretation of the data.

Conceptualization: Jung Hwan Yu, Jin-Woo Lee, Young-Joo Jin.
Data curation: Jung Hyun Lim, Jung Hwan Yu, Young Ju Suh, Jin-Woo Lee.
Formal analysis: Jung Hyun Lim, Young Ju Suh, Young-Joo Jin.
Investigation: Young-Joo Jin.
Writing – original draft: Jung Hyun Lim, Jung Hwan Yu.

References
[1] World Health Organization, World Health Organization, Global Hepatitis Programme. Global hepatitis report, 2017.
[2] Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020–2.
[3] European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908–43.
[4] Liaw Y-F, Sung JYJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–31.
[5] Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503–14.
[6] Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763–73.
[7] Terrault NA, Bowe NH, Chang K-M, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B: Hepatology, Month 2015. Hepatology 2016;63:261–83.
[8] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370–98.
[9] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2015;10:1–98.
[10] Korean Association for the Study of the Liver (KASL)/KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93–159.
[11] Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468–75.
[12] Chang T-T, Lai C-L, Yoon SK, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B. Hepatology 2010;51:422–30.
[13] Chang T-T, Liaw Y-F, Wu S-S, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886–93.
[14] Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128.
[15] Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–52.
[16] Lee SW, Choo J, Kim SJ, Lim Y-S. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:402–12.
[17] Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report. J Hepatol 2011;55:1121–31.
[18] Singh AK, Sharma MK, Hissar SS, Gupta E, Sarin SK. Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment. J Viral Hepat 2014;21:439–46.
[19] Seto W-K, Liu K, Song DK-H, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2011;55:709–16.
[20] Tseng T, Liu C, Yang H, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:3–9.
[21] Yip TC-F, Wong GL-H, Chan HL-Y, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol 2019;70:361–70.
[22] Qu L-S, Liu J-X, Zhang H-F, Zhu J, Lu C-H. Effect of serum hepatitis B surface antigen levels on predicting the clinical outcomes of chronic hepatitis B infection: a meta-analysis. Hepatol Res 2015;45:1004–13.
[23] Bruij J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology 1996;111:1018–22.
[24] Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology 1989;172:389–92.
[25] Mak L-Y, Seto W-K, Fung J, Yuen M-F. Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Rev Clin Pharmacol 2019;12:109–20.
[26] Coffin CS, Zhou K, Terrault NA. New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection. Gastroenterology 2019;156:355–68.e3.
[27] Ganem D, Prince AM. Hepatitis B Virus Infection — Natural History and Clinical Consequences. N Engl J Med 2004;350:1118–29.
[28] Zoulim F, Mimms L, Floreani M, et al. New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. J Clin Microbiol 1992;30:1111–9.
[29] Wang M, Qu N, Lu S, et al. Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma. J Med Virol 2013;85:219–27.
[30] Chan HL-Y, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011—a core group report. J Hepatol 2011;55:1121–31.
[31] Sonneveld MJ, Rijckborst V, Boucher CAB, Hansen BE, Janssen HLA. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251–7.
[32] Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151–7.
[33] Chan HL-Y, Wong VW-S, Chim AM-L, Chan H-Y, Wong GL-H, Song JJ-Y. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010;32:1323–31.
[34] Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141–50.
[35] Xun Y, Zang G, Guo J, et al. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. J Gastroenterol Hepatol 2013;28:1746–55.
[36] Jeng JW, Kim JH, Kim HS, et al. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Clin Mol Hepatol 2020;26:207–18.
[37] Tu T, Zhang H, Urban S. Hepatitis B Virus DNA integration: in vitro models for investigating viral pathogenesis and persistence. Viruses 2021;13:180.
[38] Liaw Y-F. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol 2019;16:631–41.
[39] Seto W-K, Wong DK-H, Fung J, et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS ONE 2012;7:e43087.
[40] Tseng T-C, Liu C-J, Yang H-C, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013;57:441–50.
[41] Mak L-Y, Seto W-K, Fung J, Yuen M-F. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int 2020;14:35–46.
[42] Jeng W-J, Chen Y-C, Chien R-N, Sheen I-S, Liaw Y-F. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatol Baltim Md 2019;68:425–34.
[43] Liu J, Li T, Zhang L, Xu A. The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: a systematic review. Hepatology 2019;70:1045–53.
[44] Seto W-K, Wong DK-H, Fung J, Huang F-Y, Lai C-L, Yuen M-F. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013;58:923–31.
[45] Jung YK, Kim JH, Lee YS, et al. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol 2010;44:653–7.
[46] Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titer in prediction of treatment response to entecavir. Hepatol Baltim Md 2011;53:1486–93.
[47] Zoulim F, Carosi G, Greenblom S, et al. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol 2015;62:56–63.